Navigation Links
Antibody Engineering Company F-Star Buys Back Royalty Obligations
Date:3/28/2008

TVM Capital Joins Investor Syndicate

VIENNA, Austria, March 28 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment.

Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star's founders, in collaboration with NCP, a U.S. biopharmaceutical company. After f-star's foundation, NCP became one of the Company's common shareholders and had rights to future royalty payments. In the course of the transaction, f-star has now bought back these royalty obligations and TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP's minority stake in f-star.

"We are very pleased that our technology is now essentially free of royalty obligations," Gottfried Himmler, CEO of f-star, commented on the transaction. "And we are delighted to have TVM Capital, one of the leading life science investors in Europe, joining f-star's strong international investor syndicate."

"It is an honor to become an investor in one of the leading next-generation antibody companies and to join this distinguished syndicate," Axel Polack, General Partner TVM Capital, commented.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb squared) can be created.

f-star was founded by a team of experienced antibody engineering and biotech executives in 2006. Seed-financed by Austrian government agencies and Atlas Venture, the Company recently closed a Series A financing round with Aescap Venture, Atlas Venture and Novo A/S and has raised EUR 13.0m in total so far. In its advisory board, the Company is supported by pioneers in the field of monoclonal antibodies. f-star has 18 employees at its headquarters in Vienna, Austria and recently opened a second research site in Cambridge, UK.

For more information, visit http://www.f-star.com

About the TVM Capital Life Science Practice

The TVM Capital Life Science Practice is, with EUR 900m (USD1.3bn) under management, one of the largest investors in venture and growth deals in biotechnology and pharmaceuticals in Europe, with a strong presence in the U.S. and a growing presence in Asia. The Life Science team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and more than 30 IPOs from its biotechnology and pharmaceutical portfolio of companies.
For more information, visit http://www.tvm-capital.com

Company contact:

Dr. Eugen Stermetz, CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-72055-4215

Gastgebgasse 5-13

1230 Vienna, Austria

office@f-star.com

http://www.f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78-44-940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star Biotechnologische Forschungs- und Entwicklungs-GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
2. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
3. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
4. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
5. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
6. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
7. Vaccinex Antibody Licensed to GlaxoSmithKline
8. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
9. Human Genome Sciences and Xencor Announce Antibody Collaboration
10. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
11. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will be ... growing body of knowledge during its Eighth Annual Research and Scholarship Day ... Darling Atrium. During the event, undergraduates, graduate students, and faculty members from all ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in mClinical™ ... that they were named one of the 2017 Top 10 eClinical Trial Management ... the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of the ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced ... comes after the company changed focus to making analytical tools for biopharmaceutical quality ... new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):